For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough.
For U.S. Healthcare Professionals
Clinical Data
CD Data
Clinical Data
Long term focus—From the Start
For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough.
For adult patients with moderately to severely active CD
for whom other therapies have not worked well enough.
Turn to Entyvio first to achieve remission1,2,4
Overall population
- At Week 6, 31% (n=220) of patients taking Entyvio achieved clinical response vs 26% (n=148) with placebo (P=NS) (primary end point, CD Trial I). Clinical response was defined as a ≥100-point decrease in Crohn's Disease Activity Index (CDAI) from baseline.
- In a separate study, 15% (n=158) of patients taking Entyvio who had a suboptimal response to ≥1 anti-TNFα therapy achieved clinical remission at Week 6 vs 12% (n=157) with placebo (P=NS) (primary end point, CD Trial II)
-
At Week 6, 31% (n=220) of patients taking Entyvio achieved clinical response vs 26% (n=148) with placebo (P=NS) (primary end point, CD Trial I). Clinical response was defined as a ≥100-point decrease in CDAI from baseline.
-
In a separate study, 15% (n=158) of patients taking Entyvio who had a suboptimal response to ≥1 anti-TNFα therapy achieved clinical remission at Week 6 vs 12% (n=157) with placebo (P=NS) (primary end point, CD Trial II)
CD TRIALS I, II, AND III
Three randomized, double-blind, placebo-controlled studies enrolled adult patients with moderately to severely active CD who had failed at least 1 conventional therapy, including corticosteroids, immunomodulators, and/or
≥1 anti-TNFα therapy.
In CD Trial I (N=368), patients were randomized (3:2) to receive Entyvio 300 mg or placebo by intravenous infusion at Weeks 0 and 2. The primary end point for CD Trial I was the proportion of patients with clinical remission (CDAI score ≤150) at Week 6. Another primary end point, the difference in percentage of patients who demonstrated clinical response (≥100-point decrease in CDAI score from baseline), was not statistically significant at
Week 6. Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted.
In CD Trial II (N=416), patients were randomized (1:1) to receive either Entyvio 300 mg or placebo at weeks 0, 2, and 6. A majority (76%) of enrolled patients had an inadequate response, loss of response, or intolerance to ≥1 TNF blockers; this was the primary analysis population. The primary end point for CD Trial II was the proportion of patients achieving clinical remission (CDAI score ≤150) at Week 6. Treatment with Entyvio did not result in statistically significant improvement over placebo. Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted.
In CD Trial III (N=461), patients receiving Entyvio who demonstrated clinical response (≥70-point decrease in CDAI score from baseline) at Week 6 (from CD Trial I or an open-label cohort) were randomized (1:1:1) to receive either Entyvio
300 mg every 8 weeks, Entyvio 300 mg every 4 weeks, or placebo every 4 weeks. The primary end point for CD Trial III was the proportion of patients achieving clinical remission (CDAI score ≤150) at Week 52. Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted.
CD TRIALS I, II, AND III
Three randomized, double-blind, placebo-controlled studies enrolled adult patients with moderately to severely active CD who had failed at least 1 conventional therapy, including corticosteroids, immunomodulators, and/or ≥1 anti-TNFα therapy.
In CD Trial I (N=368), patients were randomized (3:2) to receive Entyvio 300 mg or placebo by intravenous infusion at Weeks 0 and 2. The primary end point for CD Trial I was the proportion of patients with clinical remission (CDAI score ≤150) at Week 6. Another primary end point, the difference in percentage of patients who demonstrated clinical response (≥100-point decrease in CDAI score from baseline), was not statistically significant at Week 6. Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted.
In CD Trial II (N=416), patients were randomized (1:1) to receive either Entyvio 300 mg or placebo at weeks 0, 2, and 6. A majority (76%) of enrolled patients had an inadequate response, loss of response, or intolerance to ≥1 TNF blockers; this was the primary analysis population. The primary end point for CD Trial II was the proportion of patients achieving clinical remission (CDAI score ≤150) at Week 6. Treatment with Entyvio did not result in statistically significant improvement over placebo. Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted.
In CD Trial III (N=461), patients receiving Entyvio who demonstrated clinical response (≥70-point decrease in CDAI score from baseline) at Week 6 (from CD Trial I or an open-label cohort) were randomized (1:1:1) to receive either Entyvio 300 mg every 8 weeks, Entyvio 300 mg every 4 weeks, or placebo every 4 weeks. The primary end point for CD Trial III was the proportion of patients achieving clinical remission (CDAI score ≤150) at Week 52. Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted.
Anti-TNFα failure subpopulation: Remission rates1,2
Remission rates at Week 6 and Week 101,2,7
Remission rates at Week 6 and Week 101,2,7
- ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
- Infusion-related reactions and hypersensitivity reactions including anaphylaxis have occurred. Allergic reactions including dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have also been observed. If anaphylaxis or other serious allergic reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.
- Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.
- Although no cases of PML have been observed in ENTYVIO clinical trials, JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death has occurred in patients treated with another integrin receptor antagonist. A risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
- There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.
- Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.
- Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.
Indications
Adult Ulcerative Colitis (UC)
ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for inducing and maintaining clinical response, inducing and maintaining clinical remission, improving endoscopic appearance of the mucosa, and achieving corticosteroid-free remission.
Adult Crohn’s Disease (CD)
ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission.
Please see
- Entyvio [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.
- Data on file. Takeda Pharmaceuticals America, Inc. Deerfield, IL.
- Feagan BG, Rutgeerts P, Sands BE, et al; for the GEMINI 1 Study Group. N Engl J Med. 2013;369(8):699-710.
- Sandborn WJ, Feagan BG, Rutgeerts P, et al; for GEMINI 2 Study Group. N Engl J Med. 2013;369(8):711-721.
- Colombel JF, Sands BE, Rutgeerts P, et al. Gut. 2016. doi:10.1136/gutjnl-2015-311079.
- Feagan BG, Rubin DT, Danese S, et al. Clin Gastroenterol Hepatol. 2017;15(2):229-239.e5.
- Sands BE, Feagan BG, Rutgeerts P, et al. Gastroenterology. 2014;147(3):618-627.e3.
- Xavier RJ, Podolsky DK. Nature. 2007;448(7152):427-434.
- Briskin M, Winsor-Hines D, Shyjan A, et al. Am J Pathol. 1997;151(1):97-110.